Epstein Secrets

rs behind bars." The case was investigated by the Ocala Police Department and the FBI. Maryland Woman Pleads Guilty To Paying Bribes To DC Police. The Washington Patch (11/23, O'Connell, 1.03M) reports, "A Maryland woman pleaded guilty in federal court Thursday to paying more than $6,500 in bribes to an employee of

58 percent are now likely to be vaccinated, up from a low of 50 percent in September, though 42 percent still say they won't get the vaccine." In a Washington Post (11/23, 14.2M) op-ed, former Rep. John Delaney (D-MD) contends that to convince Americans to get vaccinated, the "solution is simple: Pay people to

ing an experimental vaccine from Sanofi/GSK and one from startup Novavax, which are expected to begin large trials in the U.S. in the coming weeks. Merck, which has received far less funding, is a few months further behind." Some Countries Face "Immense" Stakes With AstraZeneca's Vaccine. Bloomberg (1

story in Fortune. In July 1999, HP hired her as chief executive. But when you look at her career closely, Fiorina was fired by both Lucent and H.P. The Washington Post's Fact Checker gave Ms. Fiorina three Pinocchios for her "secretary to CEO" career trajectory. Yes, she worked as a secretary and became a CEO but the

huge profits. Gilead, maker of Sovaldi, has profits of around 5o percent. Biogen, Amgen and other biotech firms have profits of around 30 percent. Merck and Pfizer are seeing profits of 18 percent or more. Even if profits were cut by a third or a half, there would be sufficient incentive to assume th

00044434 The Daily 202: Trump is mum on Hong Kong as mobs attack protesters and China challenges U.S. influence From The Washington Post To M, The Washington Post Date 2019/07,22 10:28 The Daily 202: Trump is mum on Hong Kong as mobs attack protesters and China challenges U.S. influence Attachments: TEXT.htm, M

Ebola epidemic has killed more than 1,700 people. World Health Organization officials say they have 245,000 doses of an experimental vaccine from Merck that's already in use and that they need additional options. But health leaders in the Democratic Republic of Congo are reluctant to roll out the